secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001437749-25-026195
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q2 net loss widens to $19.2M; advances nsPFA clinical programs with FDA IDE submissions
--------------------------------------------------------------------------------

- GAAP net loss ($19.2M) vs ($11.4M) YoY; non-GAAP net loss ($13.7M) vs ($9.0M).
- Cash $106.3M at June 30 (down from $119.3M at March 31); operating cash burn $12.8M in Q2.
- FDA IDE applications submitted for nsPFA cardiac surgical clamp and 360° catheter AF pivotal studies.
- Over 140 benign thyroid nodule patients treated; expanded pilot program; post-market study enrollment planned Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925026195/0001437749-25-026195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925026195/plse20250604_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer